Exploration of the serum metabolite signature in patients with rheumatoid arthritis using gas chromatography–mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 127, Issue , 2016, Pages 60-67

  Zhou, Jia ^a   Chen, Jiao ^a   Hu, Changfeng ^a   Xie, Zhijun ^a   Li, Haichang ^a   Wei, Shuangshuang ^a   Wang, Dawei ^a   Wen, Chengping ^a   Xu, Guowang ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

Author keywords

Disease associated metabolites; GC MS; Metabolomics; Rheumatoid arthritis; Serum

Indexed keywords

2 AMINOBUTYRATE; 2 OXOISOCAPROIC ACID; 3 HYDROXYBUTANOATE; 5,8,11 ICOSATRIENOIC ACID; ALANINE; ARACHIDONIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DOCOSAHEXAENOIC ACID; EICOSANOATE; GLUCOSE; GLYCEROL STEARATE; HEXADECANOATE; ISOLEUCINE; LEUCINE; LYSINE; MANNOSE; METHIONINE; OLEIC ACID; PALMITELAIDATE; PHENYLALANINE; PROLINE; PYROGLUTAMIC ACID; SERINE; THREONINE; TRANS 4 HYDROXY DEXTRO PROLINE; TYROSINE; UNCLASSIFIED DRUG; URATE; VALINE; RHEUMATOID FACTOR;

ADULT; AMINO ACID METABOLISM; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CITRIC ACID CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERIVATIZATION; DISCRIMINANT ANALYSIS; ENERGY CONSUMPTION; ERYTHROCYTE SEDIMENTATION RATE; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FEMALE; GLUCOSE BLOOD LEVEL; GLYCOLYSIS; HUMAN; MALE; MASS FRAGMENTOGRAPHY; METABOLISM; MIDDLE AGED; PARTIAL LEAST SQUARES REGRESSION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UREA CYCLE; BLOOD; CASE CONTROL STUDY; METABOLOME; MULTIVARIATE ANALYSIS;

ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; MIDDLE AGED; MULTIVARIATE ANALYSIS; RHEUMATOID FACTOR;

EID: 84957397597     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2016.02.004     Document Type: Article

References (50)

1. [1] Feldmann, M., Brennan, F.M., Maini, R.N., Rheumatoid arthritis. Cell 85 (1996), 307–310.
2. [2] Wordsworth, P., Bell, J., Polygenic susceptibility in rheumatoid arthritis. Ann. Rheum. Dis. 50 (1991), 343–346.
3. [3] Ziff, M., Rheumatoid arthritis—its present and future. J.Rheumatol. 17 (1990), 127–133.
4. [4] Noss, E.H., Brenner, M.B., The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol. Rev. 223 (2008), 252–270.
5. [5] Maseda, D., Bonami, R.H., Crofford, L.J., Regulation of B lymphocytes and plasma cells by innate immune mechanisms and stromal cells in rheumatoid arthritis. Expert Rev. Clin. Immunol. 10 (2014), 747–762.
6. [6] Feng, Z.J., Zhang, S.L., Wen, H.F., Liang, Y., Association of rs2075876 polymorphism of AIRE gene with rheumatoid arthritis risk. Hum. Immunol. 76 (2015), 281–285.
7. [7] Karlson, E.W., Lee, I.M., Cook, N.R., Manson, J.E., Buring, J.E., Hennekens, C.H., A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum. 42 (1999), 910–917.
8. [8] Yousefi, B., Jadidi-Niaragh, F., Azizi, G., Hajighasemi, F., Mirshafiey, A., The role of leukotrienes in immunopathogenesis of rheumatoid arthritis. Mod. Rheumatol. 24 (2014), 225–235.
9. [9] Jiang, X., Trouw, L.A., van Wesemael, T.J., Shi, J., Bengtsson, C., Kallberg, H., Malmstrom, V., Israelsson, L., Hreggvidsdottir, H., Verduijn, W., Klareskog, L., Alfredsson, L., Huizinga, T.W., Toes, R.E., Lundberg, K., van der Woude, D., Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann. Rheum. Dis. 73 (2014), 1761–1768.
10. [10] Yoshida, K., Hashimoto, T., Sakai, Y., Hashiramoto, A., Involvement of the circadian rhythm and inflammatory cytokines in the pathogenesis of rheumatoid arthritis. J. Immunol. Res., 2014, 2014, 282495.
11. [11] Yeo, L., Adlard, N., Biehl, M., Juarez, M., Smallie, T., Snow, M., Buckley, C.D., Raza, K., Filer, A., Scheel-Toellner, D., Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis. Ann. Rheum. Dis.(April (9)), 2015, 10.1136/annrheumdis-2014-206921.
12. [12] Cunnane, G., Fitzgerald, O., Beeton, C., Cawston, T.E., Bresnihan, B., Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis. Arthritis Rheum. 44 (2001), 2263–2274.
13. [13] Muller, N., Doring, F., Klapper, M., Neumann, K., Schulte, D.M., Turk, K., Schroder, J.O., Zeuner, R.A., Freitag-Wolf, S., Schreiber, S., Laudes, M., Interleukin-6 and tumour necrosis factor-alpha differentially regulate lincRNA transcripts in cells of the innate immune system in vivo in human subjects with rheumatoid arthritis. Cytokine 68 (2014), 65–68.
14. [14] Yarwood, A., Martin, P., Bowes, J., Lunt, M., Worthington, J., Barton, A., Eyre, S., Enrichment of vitamin D response elements in RA-associated loci supports a role for vitamin D in the pathogenesis of RA. Genes Immun. 14 (2013), 325–329.
15. [15] Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O. 3rd, Birnbaum, N.S., Burmester, G.R., Bykerk, V.P., Cohen, M.D., Combe, B., Costenbader, K.H., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J.M., Hobbs, K., Huizinga, T.W., Kavanaugh, A., Kay, J., Kvien, T.K., Laing, T., Mease, P., Menard, H.A., Moreland, L.W., Naden, R.L., Pincus, T., Smolen, J.S., Stanislawska-Biernat, E., Symmons, D., Tak, P.P., Upchurch, K.S., Vencovsky, J., Wolfe, F., Hawker, G., Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62 (2010), 2569–2581.
16. [16] Masi, A.T., Feigenbaum, S.L., Seronegative rheumatoid arthritis. Fact or fiction?. Arch. Intern. Med. 143 (1983), 2167–2172.
17. [17] Lichtenstein, M.J., Pincus, T., Rheumatoid arthritis identified in population based cross sectional studies: low prevalence of rheumatoid factor. J. Rheumatol. 18 (1991), 989–993.
18. [18] Avcin, T., Cimaz, R., Falcini, F., Zulian, F., Martini, G., Simonini, G., Porenta-Besic, V., Cecchini, G., Borghi, M.O., Meroni, P.L., Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann. Rheum. Dis. 61 (2002), 608–611.
19. [19] Bogliolo, L., Alpini, C., Caporali, R., Scire, C.A., Moratti, R., Montecucco, C., Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J. Rheumatol. 32 (2005), 511–515.
20. [20] Hoffman, I.E., Peene, I., Cebecauer, L., Isenberg, D., Huizinga, T.W., Union, A., Meheus, L., De Bosschere, K., Hulstaert, F., Veys, E.M., De Keyser, F., Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann. Rheum. Dis. 64 (2005), 330–332.
21. [21] Hromadnikova, I., Stechova, K., Pavla, V., Hridelova, D., Houbova, B., Voslarova, S., Nekvasilova, H., Vavrinec, J., Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Autoimmunity 35 (2002), 397–401.
22. [22] Madsen, R., Lundstedt, T., Trygg, J., Chemometrics in metabolomics—a review in human disease diagnosis. Anal. Chim. Acta 659 (2010), 23–33.
23. [23] Priori, R., Scrivo, R., Brandt, J., Valerio, M., Casadei, L., Valesini, G., Manetti, C., Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun. Rev. 12 (2013), 1022–1030.
24. [24] Williamson, M.P., Humm, G., Crisp, A.J., 1H nuclear magnetic resonance investigation of synovial fluid components in osteoarthritis, rheumatoid arthritis and traumatic effusions. Br. J. Rheumatol. 28 (1989), 23–27.
25. [25] Naughton, D., Whelan, M., Smith, E.C., Williams, R., Blake, D.R., Grootveld, M., An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy. FEBS Lett. 317 (1993), 135–138.
26. [26] Naughton, D.P., Haywood, R., Blake, D.R., Edmonds, S., Hawkes, G.E., Grootveld, M., A comparative evaluation of the metabolic profiles of normal and inflammatory knee-joint synovial fluids by high resolution proton NMR spectroscopy. FEBS Lett. 332 (1993), 221–225.
27. [27] Qi, Y., Pi, Z., Liu, S., Song, F., Lin, N., Liu, Z., A metabonomic study of adjuvant-induced arthritis in rats using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Mol. Biosyst. 10 (2014), 2617–2625.
28. [28] Qi, Y., Li, S., Pi, Z., Song, F., Lin, N., Liu, S., Liu, Z., Metabonomic study of Wu-tou decoction in adjuvant-induced arthritis rat using ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 953–954 (2014), 11–19.
29. [29] Koek, M.M., Jellema, R.H., van der Greef, J., Tas, A.C., Hankemeier, T., Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics 7 (2011), 307–328.
30. [30] Ye, G., Liu, Y., Yin, P., Zeng, Z., Huang, Q., Kong, H., Lu, X., Zhong, L., Zhang, Z., Xu, G., Study of induction chemotherapy efficacy in oral squamous cell carcinoma using pseudotargeted metabolomics. J. Proteome Res. 13 (2014), 1994–2004.
31. [31] Sangster, T., Major, H., Plumb, R., Wilson, A.J., Wilson, I.D., A pragmatic and readily implemented quality control strategy for HPLC–MS and GC–MS-based metabonomic analysis. Analyst 131 (2006), 1075–1078.
32. [32] Want, E.J., Wilson, I.D., Gika, H., Theodoridis, G., Plumb, R.S., Shockcor, J., Holmes, E., Nicholson, J.K., Global metabolic profiling procedures for urine using UPLC–MS. Nat. Protoc. 5 (2010), 1005–1018.
33. [33] Smilde, A.K., van der Werf, M.J., Bijlsma, S., van der Werff-van, B.J.C., Jellema, R.H., Fusion of mass spectrometry-based metabolomics data. Anal. Chem. 77 (2005), 6729–6736.
34. [34] Wang, H., Ye, J., Regulation of energy balance by inflammation: common theme in physiology and pathology. Rev. Endocr. Metab. Disord. 16 (2015), 47–54.
35. [35] Mero, A., Leucine supplementation and intensive training. Sports Med. 27 (1999), 347–358.
36. [36] Du, Y., Meng, Q., Zhang, Q., Guo, F., Isoleucine or valine deprivation stimulates fat loss via increasing energy expenditure and regulating lipid metabolism in WAT. Amino Acids 43 (2012), 725–734.
37. [37] Jiang, M., Chen, T., Feng, H., Zhang, Y., Li, L., Zhao, A., Niu, X., Liang, F., Wang, M., Zhan, J., Lu, C., He, X., Xiao, L., Jia, W., Lu, A., Serum metabolic signatures of four types of human arthritis. J. Proteome Res. 12 (2013), 3769–3779.
38. [38] Madsen, R.K., Lundstedt, T., Gabrielsson, J., Sennbro, C.J., Alenius, G.M., Moritz, T., Rantapaa-Dahlqvist, S., Trygg, J., Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res. Ther., 13, 2011, R19.
39. [39] Pandhare, J., Donald, S.P., Cooper, S.K., Phang, J.M., Regulation and function of proline oxidase under nutrient stress. J. Cell. Biochem. 107 (2009), 759–768.
40. [40] Gu, Y., Lu, C., Zha, Q., Kong, H., Lu, X., Lu, A., Xu, G., Plasma metabonomics study of matoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry. Mol. Biosyst. 8 (2012), 1535–1543.
41. [41] Sainsbury, C.A., Sattar, N., Connell, J.M., Hillier, C., Petrie, J.R., Non-esterified fatty acids impair endothelium-dependent vasodilation in rat mesenteric resistance vessels. Clin. Sci. (Lond.) 107 (2004), 625–629.
42. [42] Sieber, J., Lindenmeyer, M.T., Kampe, K., Campbell, K.N., Cohen, C.D., Hopfer, H., Mundel, P., Jehle, A.W., Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids. Am. J. Physiol. Renal Physiol. 299 (2010), F821–829.
43. [43] Wu, J.H., Lemaitre, R.N., Imamura, F., King, I.B., Song, X., Spiegelman, D., Siscovick, D.S., Mozaffarian, D., Fatty acids in the de novo lipogenesis pathway and risk of coronary heart disease: the Cardiovascular Health Study. Am. J. Clin. Nutr. 94 (2011), 431–438.
44. [44] Carrillo, C., Cavia Mdel, M., Alonso-Torre, S., Role of oleic acid in immune system; mechanism of action; a review. Nutr. Hosp. 27 (2012), 978–990.
45. [45] He, H., Ren, X., Wang, X., Shi, X., Wang, X., Ding, Z., Gao, P., Xu, G., Therapeutic effect of Yunnan Baiyao on rheumatoid arthritis was partially due to regulating arachidonic acid metabolism in osteoblasts. J. Pharm. Biomed. Anal. 59 (2012), 130–137.
46. [46] Calder, P.C., n-3 polyunsaturated fatty acids inflammation, and inflammatory diseases. Am. J. Clin. Nutr. 83 (2006), 1505S–1519S.
47. [47] Bucher, H.C., Hengstler, P., Schindler, C., Meier, G., N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am. J. Med. 112 (2002), 298–304.
48. [48] Carrie, I., Abellan Van Kan, G., Rolland, Y., Gillette-Guyonnet, S., Vellas, B., PUFA for prevention and treatment of dementia?. Curr. Pharm. Des. 15 (2009), 4173–4185.
49. [49] Prostek, Adam, Gajewska, Małgorzata, Kamola, Dariusz, Bałasińska, B., The influence of EPA and DHA on markers of inflammation in 3T3-L1 cells at different stages of cellular maturation. Lipids Health Dis., 13, 2014, 3.
50. [50] Tall, A.R., Yvan-Charvet, L., Cholesterol, inflammation and innate immunity. Nat. Rev. Immunol. 15 (2015), 104–116.